Moore Capital Management, LP Ultragenyx Pharmaceutical Inc. Transaction History
Moore Capital Management, LP
- $6.28 Billion
- Q3 2025
A detailed history of Moore Capital Management, LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Moore Capital Management, LP holds 270,000 shares of RARE stock, worth $8.93 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
270,000
Previous 290,000
6.9%
Holding current value
$8.93 Million
Previous $10.5 Million
22.98%
% of portfolio
0.13%
Previous 0.15%
Shares
8 transactions
Others Institutions Holding RARE
# of Institutions
351Shares Held
88.3MCall Options Held
2.23MPut Options Held
1.06M-
Vanguard Group Inc Valley Forge, PA10.1MShares$335 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$185 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY4.01MShares$133 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.77MShares$125 Million0.33% of portfolio
-
State Street Corp Boston, MA3.69MShares$122 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.32B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...